These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34797941)

  • 1. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.
    Cao XX; Duan MH; Zhao AL; Cai H; Chen J; Gao XM; Liu T; Cai HC; Zhang L; Sun J; Liang ZY; Zhou DB; Li J
    Am J Hematol; 2022 Feb; 97(2):203-208. PubMed ID: 34797941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation and prognostic analysis of adult patients with Langerhans cell histiocytosis with pulmonary involvement.
    Miao HL; Zhao AL; Duan MH; Zhou DB; Cao XX; Li J
    BMC Cancer; 2020 Sep; 20(1):911. PubMed ID: 32967635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.
    Chang L; Lang M; Lin H; Cai H; Duan MH; Zhou DB; Cao XX
    Leukemia; 2024 Apr; 38(4):803-809. PubMed ID: 38388646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and prognostic features of Langerhans cell histiocytosis in adults.
    Sato A; Kobayashi M; Yusa N; Ogawa M; Shimizu E; Kawamata T; Yokoyama K; Ota Y; Ichinohe T; Ohno H; Mori Y; Sakaida E; Kondo T; Imoto S; Nannya Y; Mitani K; Tojo A
    Cancer Sci; 2023 Sep; 114(9):3687-3697. PubMed ID: 37364599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
    Wu FF; Gao YJ; Pan C; Chen J; Tang JY
    Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study.
    Cai HC; Chen J; Liu T; Cai H; Duan MH; Li J; Zhou DB; Cao XX
    Orphanet J Rare Dis; 2022 Jul; 17(1):268. PubMed ID: 35841042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy.
    Wang CJ; Zhu T; Zhao CZ; Cui H; Wang D; Zhao ZJ; Huang XT; Li HL; Liu FF; Zhang R; Li ZG; Cui L
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31099. PubMed ID: 38845144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
    Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
    Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric langerhans cell histiocytosis: single center experience over a 17-year period.
    İnce D; Demirağ B; Özek G; Erbay A; Ortaç R; Oymak Y; Kamer S; Yaman Y; Kundak S; Vergin C
    Turk J Pediatr; 2016; 58(4):349-355. PubMed ID: 28276205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Risk Model Composed of Complete Blood Count,
    Wang L; Yuan L; Du X; Zhou K; Yang Y; Qin Q; Yang L; Xiang Y; Qu X; Liu H; Qin X; Liu C
    Front Oncol; 2022; 12():800786. PubMed ID: 35186740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis.
    Minkov M; Pötschger U; Thacker N; Astigarraga I; Braier J; Donadieu J; Henter JI; Lehrnbecher T; Rodriguez-Galindo C; Sieni E; Nanduri V; van den Bos C; Abla O;
    J Pediatr; 2021 Oct; 237():65-70.e3. PubMed ID: 34146548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 20. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
    Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.